Sickle Cell Kidney Biorepository
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- University of Texas Southwestern Medical Center
- Study ID
- NCT07064174
- Status
- Recruiting
Conditions
- Chronic Kidney Disease
- Sickle Cell Disease (SCD)
- Sickle Cell Trait
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Study Details
Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.
Key Dates
- Start date
- Aug 22, 2024
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2049
- Completion
- Dec 31, 2049
Study Design
- Enrollment
- 800 participants (estimated)
Primary Outcome Measure
Kidney function decline [ Time Frame: 10 years ]
Central Contacts
- Kabir O Olaniran, MD, MPH, FASN214-645-8267
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Parkland Memorial Hospital | Dallas | Texas | 75235 | Kabir O Olaniran, MD, MPH, FASN (PRINCIPAL_INVESTIGATOR) |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Kabir O Olaniran, MD, MPH, FASN (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Dallas, TX
Related Studies
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPHASE3 · Recruiting · Amgen · Los Angeles, California
- L-arginine to Reduce Sympathetic Nerve Activity in CKD PatientsPHASE4 · Recruiting · The University of Texas at Arlington · Newark, Delaware
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona